Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients

Gut

Volumn 57, Issue 6, 2008, Pages 872-

  Derijks, Luc J J ^a   Van Helden, R B ^b   Hommes, D W ^b   Stokkers, P C ^c  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB;

ADULT; CASE REPORT; CROHN DISEASE; ENTERITIS; GENOTYPE; HOMOZYGOSITY; HUMAN; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MALE; MONOTHERAPY; PANCYTOPENIA; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; PANCYTOPENIA;

EID: 44149091294     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.145912     Document Type: Letter

References (3)

1. Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004;41(Pt 4):294-302.
2. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6.
3. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004;26:311-8.